The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing support for the inflammatory hypothesis of atherosclerosis and cancer in man, demonstrating diverse clinical benefits of inhibiting IL (interleukin)-1 beta for cardiovascular events and lung cancer. Limited effects on cardiovascular mortality and safety concerns raised by a higher incidence of fatal infection warrant further studies to identify patient subgroups which profit most from anti-inflammatory therapy and a careful pursuit of alternative targets.</p
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. ...
Atherosclerosis, the underlying cause of coronary artery (CAD) and other cardiovascular diseases, is...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
Authors work in the area has been supported by UK Medical Research Council Experimental Medicine Gra...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. ...
Atherosclerosis, the underlying cause of coronary artery (CAD) and other cardiovascular diseases, is...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
Authors work in the area has been supported by UK Medical Research Council Experimental Medicine Gra...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. ...
Atherosclerosis, the underlying cause of coronary artery (CAD) and other cardiovascular diseases, is...